| 货号 | 规格 | 价格 | 上海 | 北京 | 武汉 | 南京 | 购买数量 |
|---|---|---|---|---|---|---|---|
S81128-1mg |
99.90% | ￥168.00 | >10 | - | - | - |
|
S81128-2mg |
99.90% | ￥304.00 | >10 | - | - | - |
|
S81128-5mg |
99.90% | ￥384.00 | >10 | - | - | - |
|
S81128-10mg |
99.90% | ￥640.00 | >10 | - | - | - |
|
S81128-25mg |
99.90% | ￥960.00 | >10 | - | - | - |
|
S81128-50mg |
99.90% | ￥1360.00 | >10 | - | - | - |
|
S81128-100mg |
99.90% | ￥1770.00 | >10 | - | - | - |
|
| 产品描述： | Lumacaftor (VX-809; VRT 826809) is a CFTR modulator that corrects the folding and trafficking of CFTR protein. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | EC50: 0.1 μM (CFTR);CFTR; Autophagy | ||||||||||||||||||||
| 体内研究： | Oral dosing of 1 mg/kg Lumacaftor in male Sprague-Dawley rats results in a Cmax of 2.4±1.3 μM with a t1/2 of 7.7±0.4 h (mean±SD; n=3), indicating that that Lumacaftor is orally bioavailable and able to reach plasma levels that significantly exceeded EC50s for F508del-CFTR correction | ||||||||||||||||||||
| 参考文献： | 1. Van Goor F, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18843-8. 2. Phuan PW, et al. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy. Mol Pharmacol. 2014 Jul;86(1):42-51. | ||||||||||||||||||||
| 溶解性： | DMSO : 25 mg/mL (55.26 mM; ultrasonic and warming and heat to 60°C) | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京